GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (NAS:ALBO) » Definitions » Cyclically Adjusted PS Ratio

Albireo Pharma (Albireo Pharma) Cyclically Adjusted PS Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Albireo Pharma Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Albireo Pharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Cyclically Adjusted PS Ratio Chart

Albireo Pharma Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Albireo Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Albireo Pharma's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Albireo Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Albireo Pharma's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albireo Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Albireo Pharma's Cyclically Adjusted PS Ratio falls into.



Albireo Pharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Albireo Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, Albireo Pharma's adjusted Revenue per Share data for the three months ended in Sep. 2022 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=0.5/125.2265*125.2265
=0.500

Current CPI (Sep. 2022) = 125.2265.

Albireo Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201212 0.000 96.871 0.000
201303 0.000 98.209 0.000
201306 0.000 98.518 0.000
201309 0.000 98.790 0.000
201312 0.000 98.326 0.000
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 1.028 105.290 1.223
201806 0.061 106.317 0.072
201809 0.020 106.507 0.024
201812 0.048 105.998 0.057
201903 0.047 107.251 0.055
201906 0.101 108.070 0.117
201909 0.109 108.329 0.126
201912 0.506 108.420 0.584
202003 0.110 108.902 0.126
202006 0.128 108.767 0.147
202009 0.136 109.815 0.155
202012 0.142 109.897 0.162
202103 0.103 111.754 0.115
202106 0.126 114.631 0.138
202109 0.186 115.734 0.201
202112 1.686 117.630 1.795
202203 0.353 121.301 0.364
202206 0.419 125.017 0.420
202209 0.500 125.227 0.500

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Albireo Pharma  (NAS:ALBO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Albireo Pharma Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Albireo Pharma (Albireo Pharma) Business Description

Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.
Executives
Harford Simon N.r. officer: CFO and Treasurer AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Pamela Stephenson officer: Chief Commercial Officer C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Martha J. Carter officer: Chief Regulatory Officer C/O AEGERION PHARMACEUTICALS, INC., 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Jan Mattsson officer: Chief Operating Officer C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109
Cooper Ronald Harold Wilfred director, officer: President and CEO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Michelle Graham officer: Chief Human Resources Officer 10000 WEHRLE DRIVE, CLARENCE NY 14031
Jason Duncan officer: General Counsel C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Paul Streck officer: Chief Medical Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Craig C. Hopkinson director 852 WINTER STREET, WALTHAM MA 02451
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Susan Alesina director C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON MA 02109
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Patrick Taylor Horn officer: Chief Medical Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003